药物治疗只能改善四肢运动,而深度大脑刺激则可以改善视觉导向伸手期间的眼睛和四肢运动
Miranda J Munoz1, Rishabh Arora1,2, Yessenia M Rivera1
1Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, United States.
Frontiers in human neuroscience
|October 18, 2023
概括
帕金森病 (PD) 治疗对眼睛和四肢运动有不同的影响. 抗帕金森症药物恶化了动的表现,但改善了四肢的伸展,而下丘脑核深度大脑刺激 (STN-DBS) 对两者都有好处.
科学领域:
- 神经科学是一个神经科学.
- 运动障碍 运动障碍
- 帕金森病研究 帕金森病研究
背景情况:
- 帕金森病 (PD) 影响骨运动控制,治疗方法如抗帕金森药物和下丘脑核深脑刺激 (STN-DBS) 是常见的.
- 虽然对四肢运动有效,但这些治疗方法可能会对眼睛和四肢运动产生不同的影响,尽管共享基底腺节电路.
- 了解这些差异性影响对于优化PD管理至关重要.
研究的目的:
- 调查抗帕金森症药物和STN-DBS对眼睛和上肢运动表现的明显影响.
- 使用需要整合眼肢协调的任务来比较治疗影响.
- 阐明观察到的运动变化的神经生理基础.
主要方法:
- 视觉引导的伸手任务用于评估眼睛和上肢运动.
- 从PD患者收集的数据测试了开启和关闭药物 (n=34) 和双边STN-DBS的开启/关闭 (n=11).
- 包括规范性数据的健康老年人 (n=14) 的比较组.
主要成果:
- 抗帕金森药物增加了萨卡德延迟和降低了萨卡德峰值速度,但改善了达到峰值速度.
- 双边STN-DBS降低了saccade延迟,并增加了saccade和达到峰值的速度.
- 两种治疗都没有改变到达反应时间;观察到萨卡德延迟和到达RT之间的持续正相关性.
结论:
- 抗帕金森症药物损害了摇的表现,同时提高了四肢的伸展能力.
- 在STN-DBS的研究中,STN-DBS证明了它对跳动和伸展运动都有好处.
- 研究结果表明,药物与STN-DBS对控制不同运动类型的基底腺回路的生理效应不同.
相关概念视频
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
Parkinson's Disease: Overview
567
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
567


